Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-551 versus placebo in adults with neuromyelitis optica spectrum disorders
NL-OMON46416Phase 2Completed
- Sponsor
- MedImmune
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Neuromyelitis Optica Spectrum Disorder (NMOSD) and neuromyelitis optica (NMO) comparing MEDI-551 randomized-controlled arm with Placebo randomized-controlled arm (2 arms). Primary endpoint: Time to adjudicated NMO/NMOSD attack by Day 197. Started Nov 2011; status: completed.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)neuromyelitis optica (NMO)
Beyond the preview
Go deeper on NL-OMON46416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46416.